Clevexel Pharma SAS-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Clevexel Pharma SAS - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014293
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:フランス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Clevexel Pharma SAS (Clevexel) is a drug development company that develops drugs to treat diseases of the central nervous system. The company’s pipeline product portfolio includes CVXL-0107, a glutamate release inhibitor developed to improve the quality of life for Parkinson’s disease patients; CVXL-0069, a dual A2A/A1 antagonist that concentrates on the treatment of motor and non-motor symptoms of Parkinson’s disease. It operates drug development site covering all phases from preclinical to early clinical developments. Clevexel offers drug development tools to its partners and clients. The company works in partnership with Institut du Cerveau et de la Moelle Epiniere for development of new treatments in the field of neurodegenerative diseases. Clevexel is headquartered in Paris, France.

Clevexel Pharma SAS – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Clevexel Pharma SAS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Clevexel Pharma SAS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Clevexel Pharma SAS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Clevexel Pharma SAS, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Clevexel Pharma SAS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Clevexel Pharma SAS, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
CleveXel Pharma Acquires Development Center From Teva Pharma 10
Partnerships 11
Clevexel Pharma Enters into Agreement with ICM 11
PEP-Therapy Enters into Co-Development Agreement with CleveXel Pharma 12
CleveXel Pharma Enters into Co-Development Agreement with Guilin Pharma for Anti-Malarial Products 13
CleveXel Pharma Enters Into Co-Development Agreement With Dynamix Pharma 14
Umecrine Enters Into Co-Development Agreement With CleveXel 15
Licensing Agreements 16
Clevexel Pharma Enters into Licensing Agreement with Domain Therapeutics 16
Clevexel Pharma Enters into Licensing Agreement with Kaldi Pharma 17
CleveXel Pharma Enters into Licensing Agreement with Satt Sud Est 18
Clevexel Pharma SAS – Key Competitors 19
Clevexel Pharma SAS – Key Employees 20
Clevexel Pharma SAS – Locations And Subsidiaries 21
Head Office 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
Clevexel Pharma SAS, Pharmaceuticals & Healthcare, Key Facts 2
Clevexel Pharma SAS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Clevexel Pharma SAS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Clevexel Pharma SAS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Clevexel Pharma SAS, Deals By Therapy Area, 2011 to YTD 2017 8
Clevexel Pharma SAS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
CleveXel Pharma Acquires Development Center From Teva Pharma 10
Clevexel Pharma Enters into Agreement with ICM 11
PEP-Therapy Enters into Co-Development Agreement with CleveXel Pharma 12
CleveXel Pharma Enters into Co-Development Agreement with Guilin Pharma for Anti-Malarial Products 13
CleveXel Pharma Enters Into Co-Development Agreement With Dynamix Pharma 14
Umecrine Enters Into Co-Development Agreement With CleveXel 15
Clevexel Pharma Enters into Licensing Agreement with Domain Therapeutics 16
Clevexel Pharma Enters into Licensing Agreement with Kaldi Pharma 17
CleveXel Pharma Enters into Licensing Agreement with Satt Sud Est 18
Clevexel Pharma SAS, Key Competitors 19
Clevexel Pharma SAS, Key Employees 20

★海外企業調査レポート[Clevexel Pharma SAS-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Arix Bioscience PLC:企業のM&A・事業提携・投資動向
    Arix Bioscience PLC - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Arix Bioscience PLC Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), …
  • Eurazeo SA (RF):企業の財務・戦略的SWOT分析
    Summary Eurazeo SA (Eurazeo) is an investment service provider that offers investment services. The company offers detection and acquisition, retention and divestment and enhancement programs. It provides retention services such as CSR reporting, deployment of CSR essentials, drafting, monitoring an …
  • Theratechnologies Inc (TH):製薬・医療:M&Aディール及び事業提携情報
    Summary Theratechnologies Inc (Theratechnologies) is a pharmaceutical company that focuses on the discovery and development of drugs for metabolic disorders. The company develops therapeutic peptide products, with an emphasis on growth releasing factor (GRF) peptides. Its lead products include Egrif …
  • Polskie Sieci Elektroenergetyczne SA:企業の戦略的SWOT分析
    Polskie Sieci Elektroenergetyczne SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • Toshiba Corporation:企業の戦略・SWOT・財務情報
    Toshiba Corporation - Strategy, SWOT and Corporate Finance Report Summary Toshiba Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • LSK BioPartners Inc-製薬・医療分野:企業M&A・提携分析
    Summary LSK BioPartners Inc (LSK BioPartners) dba LSK BioPharma is a biopharmaceutical company which develops therapies for unmet medical needs in cancer. The company is developing proprietary drug candidate apatinib, a selective VEGFR-2 inhibitor for the treatment of solid tumor cancers such as met …
  • Canon Machinery Inc:企業の戦略的SWOT分析
    Canon Machinery Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and se …
  • Korn/Ferry International:企業の戦略・SWOT・財務情報
    Korn/Ferry International - Strategy, SWOT and Corporate Finance Report Summary Korn/Ferry International - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Indoco Remedies Ltd (INDOCO):企業の財務・戦略的SWOT分析
    Summary Indoco Remedies Ltd (Indoco Remedies) is a research-oriented pharmaceutical company that manufactures and markets formulations (finished dosage forms) and active pharmaceutical ingredients (APIs). It has products portfolio in various therapeutic segments such as cardiovascular, central nervo …
  • Chrono Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Chrono Therapeutics Inc (CTI) is a personalized medicine manufacturer that provides programmable passive transdermal drug delivery products. The company provides smartstop, a programmable smoking cessation therapy that helps people to quit smoking and improve cessation outcomes. Its wearable …
  • Alecta Pensionsforsakring Omsesidigt:企業の戦略的SWOT分析
    Alecta Pensionsforsakring Omsesidigt - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and majo …
  • BioStem Technologies Inc (BSEM):製薬・医療:M&Aディール及び事業提携情報
    Summary BioStem Technologies Inc. (BioStem Technologies), formerly Caribbean International Holdings Inc., is a life sciences company that discovers, develops and manufactures pharmaceuticals and regenerative medicines. Through its subsidiaries, the company discovers, develops, produces and commercia …
  • Bonus BioGroup Ltd (BONS):医療機器:M&Aディール及び事業提携情報
    Summary Bonus BioGroup Ltd (Bonus BioGroup), formerly Oceania advanced industries Ltd is a biotechnology company that supplies tissue-engineered viable bone grafts. The company operates in the field of tissue engineering and live bone transplantation. Its products include BonoFill injectable bone gr …
  • Abu Dhabi Commercial Bank PJSC:企業の戦略・SWOT・財務情報
    Abu Dhabi Commercial Bank PJSC - Strategy, SWOT and Corporate Finance Report Summary Abu Dhabi Commercial Bank PJSC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Parker Hannifin Corporation (PH)-医療機器分野:企業M&A・提携分析
    Summary Parker Hannifin Corporation (Parker) is a manufacturer of motion and control technologies and systems. The company offers critical motion and control solutions including fluid power systems, electromechanical controls and related components. Its products find use in various industries and ap …
  • China Communications Construction Co Ltd:戦略・SWOT・企業財務分析
    China Communications Construction Co Ltd - Strategy, SWOT and Corporate Finance Report Summary China Communications Construction Co Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT …
  • Regis Corporation (RGS):企業の財務・戦略的SWOT分析
    Regis Corporation (RGS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • LyondellBasell Industries N.V.:企業の戦略・SWOT・財務情報
    LyondellBasell Industries N.V. - Strategy, SWOT and Corporate Finance Report Summary LyondellBasell Industries N.V. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product a …
  • Calumet Specialty Products Partners LP (CLMT):石油・ガス:M&Aディール及び事業提携情報
    Summary Calumet Specialty Products Partners LP (Calumet) is a downstream energy company that produces specialty hydrocarbon and fuel products. It processes crude oil and other feedstock into a wide range of solvents, lubricating oils, white mineral oils, petrolatums and waxes; and into fuel and fuel …
  • The Medicines Company (MDCO):医療機器:M&Aディール及び事業提携情報
    Summary The Medicines Company (TMC) is a biopharmaceutical company, which provides medical solutions for improving health conditions in patients under critical care. The company’s product portfolio comprises marketed products a peptide compound that inhibits an intravenous direct thrombin and needle …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆